Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is in Phase 2 clinical trial for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and in patients with myelofibrosis; and lead small molecule product candidate is KER-047 that has completed Phase 1 clinical trial to treat anemia and fibro dysplasia ossificans progressive (FOP). It is also developing KER-012 that is in preclinical studies for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension (PAH). The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.